Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04763109 · ClinicalTrials.gov registry record · NA

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

A NA study of Neurofibromatosis Type 1, sponsored by Nicole Baca.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT04763109: Recruiting NA study of Neurofibromatosis Type 1, sponsored by Nicole Baca.

NCT04763109 is a NA study of Neurofibromatosis Type 1 that is actively recruiting participants, run by Nicole Baca. The registered enrollment target is 15 participants, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04763109, a NA study of Neurofibromatosis Type 1, is actively recruiting participants, sponsored by Nicole Baca.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm, among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.

Primary Outcome

T2 is a type of high-resolution multiparametric tissue mapping that measures quantitative metrics of the physical properties of tissue and allows comparison in longitudinal follow-up

Conditions Studied

Interventions

  • OTHER Whole-body Magnetic Resonance Imaging

Study Locations (1)

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-07-08
Est. Completion 2027-05
Phase NA
Nicole Baca

1 total trials

What NCT04763109 shows while recruiting

NCT04763109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Whole-body Magnetic Resonance Imaging is the first listed.

NCT04763109 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04763109 about?

NCT04763109 is a clinical study titled "Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence". This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline t...

What is the current status of trial NCT04763109?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2022-07-08. Estimated completion is 2027-05.

What conditions does trial NCT04763109 study?

This clinical trial studies the following conditions: Neurofibromatosis Type 1.

What interventions are being tested in trial NCT04763109?

The interventions under investigation include: Whole-body Magnetic Resonance Imaging (OTHER).

Who is sponsoring clinical trial NCT04763109?

This trial is sponsored by Nicole Baca, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04763109 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurofibromatosis Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04763109's enrollment target sits among peer trials

15 16th of 17 higher than 2 of 17 other Neurofibromatosis Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neurofibromatosis Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04763109, the US trial registry maintained by the National Library of Medicine. NCT04763109 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.